You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Find out more about hepatitis B virus screening and management.

Drug Formulary
About the Drug Formulary Email Drug Formulary Team

denosumab

( den-OH-sue-mab )
Other Name(s): Xgeva® ()
Appearance: clear, colourless to slightly yellowish solution

Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

Drug Monograph

Jul 2018
Table of Contents
Eligibility Forms
pdf download Denosumab - Hormone Refractory Prostate Cancer

Patient Info Sheet

Jul 2018

What it is used for

Denosumab may:

  • Help relieve bone pain and prevent broken bones in some types of cancer that arise from or spread to the bones
  • Be used to treat giant cell tumour of bone in some patients
  • Be used to remove excess calcium in the blood that is a problem with some types of cancer, if other treatments have not worked


You might also be interested in

Funding & Reimbursement

Several payment sources exist for cancer drugs in Ontario, depending on the drug, disease indication, and how and where it is delivered.

View Funding & Reimbursement

Symptom Management

Many people living with cancer experience nausea, diarrhea and other symptoms from their treatment or disease.

View Symptom Management

Drug Safety and Administration

Find documents on drug safety and administration for healthcare providers, including calculations and recommendations.

View Drug Safety and Administration